[1] |
LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin.
Analysis of the rationality and safety of clinical application of anrotinib in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334.
|
[2] |
WANG Changshun, WANG Xiaolei, DUAN Jiping, YUAN Hao, LIU Yongli, ZHAO Ding.
Effect of sulfur fumigation on quality of Angelica dahurica and alternative processing methods in producing areas
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 355-360.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[5] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[6] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[7] |
LIU Yuanxi, GU Donglin, WANG Qi, YAO Lingwen, WANG Ying, JIN Hongyu, MA Shuangcheng.
Determination of 87 types of pesticide residues in Polygoni Multiflori Radix by LC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 601-608.
|
[8] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[9] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[10] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[11] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[12] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[13] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[14] |
ZUO Tiantian, WANG Zhao, GUO Yuansheng, WEI Feng, JIN Hongyu, MA Shuangcheng.
Non-carcinogenic and carcinogenic risk assessment of toxic elements in Panax quinquefolium L. based on multi-element semi-quantitative screening
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1108-1112.
|
[15] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|